Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancerHEYMACH, John V; JOHNSON, Bruce E; KENNEDY, Sarah J et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4270-4277, issn 0732-183X, 8 p.Article

Multicenter Phase II Trial ofYM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non―Small-Cell Lung CancerGIACCONE, Giuseppe; ZATLOUKAL, Petr; ROUBEC, Jaromir et al.Journal of clinical oncology. 2009, Vol 27, Num 27, pp 4481-4486, issn 0732-183X, 6 p.Article

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trialZATLOUKAL, Petr; PETRUZELKA, Lubos; HORENKOVA, Eva et al.Lung cancer. 2003, Vol 41, Num 3, pp 321-331, issn 0169-5002, 11 p.Article

Patient attitudes towards chemotherapy and survival: A prospective observational study in advanced non-small cell lung cancerCHU, Da-Tong; KIM, Sang-We; HSU, Hon-Ki et al.Lung cancer. 2009, Vol 66, Num 2, pp 250-256, issn 0169-5002, 7 p.Article

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer : The tarceva lung cancer investigation trialPLUZANSKA, Anna; SZCZESNA, Aleksandra; JANASKOVA, Terezie et al.Journal of clinical oncology. 2007, Vol 25, Num 12, pp 1545-1552, issn 0732-183X, 8 p.Article